{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:27:41Z","timestamp":1790706461495,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["DMR-107-019"],"award-info":[{"award-number":["DMR-107-019"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"publisher","award":["NHRI-113A1-CACO-13242402"],"award-info":[{"award-number":["NHRI-113A1-CACO-13242402"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2025.12.945","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:44:15Z","timestamp":1765593855000},"page":"563.e1-563.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["NT-proBNP Levels after First-Dose Post-Transplant Cyclophosphamide Predict Early Cardiac Events and Mortality in Allogeneic Stem Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"given":"Tzu-Ting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-6389","authenticated-orcid":false,"given":"Ching-Chan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2654-4861","authenticated-orcid":false,"given":"Chia-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Chan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yun","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Fang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2025.12.945_bib0001","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for transplantation and cellular therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.945_bib0002","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for blood and marrow transplantation","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.945_bib0003","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.945_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2021015129","article-title":"How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2025.12.945_bib0005","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.945_bib0006","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.945_bib0007","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy\u2014a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.945_bib0008","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/bloodadvances.2022008792","article-title":"Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant","volume":"7","author":"P\u00e9rez-Valencia","year":"2023","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jtct.2025.12.945_bib0009","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1182\/bloodadvances.2021004846","article-title":"Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era","volume":"5","author":"Yeh","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.12.945_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571678","article-title":"Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC","volume":"16","author":"Pinto","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.945_bib0011","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2169\/internalmedicine.44.120","article-title":"Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation","volume":"44","author":"Kamezaki","year":"2005","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.945_bib0012","article-title":"Cyclophosphamide-induced cardiomyopathy","volume":"1","author":"Dhesi","year":"2013","journal-title":"J Investig Med High Impact Case Rep"},{"key":"10.1016\/j.jtct.2025.12.945_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.945_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131394","article-title":"Mechanisms of fatal cardiotoxicity following high-dose cyclophosphamide therapy and a method for its prevention","volume":"10","author":"Nishikawa","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jtct.2025.12.945_bib0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12032-018-1221-5","article-title":"Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies","volume":"35","author":"Por\u0119ba","year":"2018","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0016","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/hrt.2003.026021","article-title":"Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population","volume":"90","author":"Groenning","year":"2004","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0017","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/ehf2.14314","article-title":"Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and meta-analysis","volume":"10","author":"Goyder","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.945_bib0018","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jvs.2008.05.015","article-title":"N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery","volume":"48","author":"Rajagopalan","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jtct.2025.12.945_bib0019","article-title":"Pharmacogenomics in drug-induced cardiotoxicity: current status and the future","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.945_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018143","article-title":"Cardiotoxicity and cardiovascular biomarkers in patients with breast cancer: data from the GeparOcto-GBG 84 trial","volume":"9","author":"R\u00fcger","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.945_bib0021","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of cardiovascular imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.945_bib0022","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41409-022-01745-z","article-title":"Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation","volume":"57","author":"Selvarajan","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.945_bib0023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of cardiovascular imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.945_bib0024","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWPEBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.945_bib0025","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.945_bib0026","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"446","key":"10.1016\/j.jtct.2025.12.945_bib0027","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0028","doi-asserted-by":"crossref","DOI":"10.2174\/1573403X17666210909170415","article-title":"Biomarkers in acute heart failure syndromes: an update","volume":"18","author":"Al-Sadawi","year":"2022","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.945_bib0029","first-page":"3","article-title":"The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications","volume":"31","author":"Moe","year":"2015","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.945_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.20042","article-title":"Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation","volume":"76","author":"Nakamae","year":"2004","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.945_bib0031","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00277-016-2654-6","article-title":"The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT)","volume":"95","author":"Ishida","year":"2016","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0032","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1703132","article-title":"Serum cardiac troponin I levels and ECG\/Echo monitoring in breast cancer patients undergoing high-dose (7g\/m2) cyclophosphamide","volume":"28","author":"Morandi","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.945_bib0033","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/IJCA.IJCA_43_20","article-title":"Early detection of cardiotoxicity in patients receiving cancer chemotherapy using three-dimensional and speckle tracking echocardiography","volume":"6","author":"Ebaid","year":"2020","journal-title":"Int J Cardiovasc Acad"},{"key":"10.1016\/j.jtct.2025.12.945_bib0034","article-title":"The role of stress echocardiography in identifying cardiotoxicity: an in-depth exploration","volume":"11","author":"Wang","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.945_bib0035","doi-asserted-by":"crossref","first-page":"70.e23","DOI":"10.1016\/j.amjmed.2005.08.041","article-title":"Incremental prognostic value of changes in B-type natriuretic peptide in heart failure","volume":"119","author":"Latini","year":"2006","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.945_bib0036","article-title":"A prognostic model based on clinical biomarkers for heart failure in adult patients following allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Zhang","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.945_bib0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.34172\/jcvtr.33230","article-title":"Post-transplant cyclophosphamide-induced cardiotoxicity: a comprehensive review","volume":"16","author":"Alizadehasl","year":"2024","journal-title":"J Cardiovasc Thorac Res"},{"issue":"Suppl 35","key":"10.1016\/j.jtct.2025.12.945_bib0038","doi-asserted-by":"crossref","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","article-title":"Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity","volume":"10","author":"Michel","year":"2018","journal-title":"J Thorac Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.945_bib0039","doi-asserted-by":"crossref","first-page":"520","DOI":"10.6004\/jadpro.2023.14.6.5","article-title":"Post-transplant cyclophosphamide for the prevention of graft-vs.-host disease in allogeneic hematopoietic cell transplantation: a guide to management for the advanced practitioner","volume":"14","author":"Kachur","year":"2023","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0040","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.19228","article-title":"Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation","volume":"204","author":"Fuji","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.945_bib0041","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.12.945_bib0042","first-page":"1","article-title":"Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity","author":"Lazana","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.945_bib0043","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.18483","volume":"200","author":"Zhang","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0044","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.945_bib0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-024-00990-3","volume":"14","author":"Brissot","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.46989\/001c.140766","article-title":"The short-term cardiotoxicity after allogeneic hematopoietic stem cell transplantation: a retrospective single center experience","volume":"7","author":"Cheikh","year":"2025","journal-title":"Clin Hematol Int"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.945_bib0047","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.jtct.2023.10.011","article-title":"Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning and post-transplant cyclophosphamide prophylaxis in patients with reduced systolic function","volume":"30","author":"LeMaistre","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.945_bib0048","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bmt.1702507","article-title":"Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide","volume":"26","author":"Snowden","year":"2000","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:06:47Z","timestamp":1780312007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725026004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636725026004"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.945","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NT-proBNP Levels after First-Dose Post-Transplant Cyclophosphamide Predict Early Cardiac Events and Mortality in Allogeneic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}